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Osseous metastasesAbstract Purpose: The goal of the study was to illustrate the added value of combined 18F-FDG
PET/CT over isolated CT for detection of osseous metastases in cancer patients.
Patients and methods: The study included 53 patients divided into five groups of primary malignan-
cies. 18F-PET/CT scans were performed. In this study, a lesion based analysis was performed
in detailed retrograde matter for a total of 386 detected osseous lesions on CT and fused
images of 18F-PET/CT. Statistical analysis including specificity, Sensitivity, negative predictive
value (NPV) and positive predictive value (PPV) of each of these modalities was calculated. A final
diagnosis of metastasis was confirmed by biopsy or by further clinical and radiologic workup.
Results: According to lesion based analysis, the 18F-PET/CT showed 100% sensitivity, 80.8%
specificity, 98.6% PPV, 100% NPV and 98.7% accuracy compared with 93.9%, 34.6%, 95.2%,
29% and 89.9%, respectively, for CT. Significant improvement of the sensitivity and specificity
was found in combined 18F-PET/CT than in CT alone.
Conclusion: Combined 18-F FDG PET/CT significantly improves the sensitivity and specificity of
isolated CT for the detection of osseous metastases.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Metastases are the commonest malignant tumors involving the
bony skeleton. Imaging is very important in the diagnosis,
detection, planning of treatment and prognostication as well
as for follow-up of metastatic boney lesions. In patients with
proven non-skeletal tumors, imaging is useful for screeningthe skeleton to assess metastatic disease and, if it is present,
to determine its extent (1–3). Multislice spiral CT enables
imaging of all of the skeleton without any superposition effects
and so much more suitable for the accurate detection of metas-
tases especially in anatomically complex zones as the spine. CT
is highly sensitive for the osteolytic as well as osteoplastic bone
lesions affecting cortical bone, but less so for tumors confined
to the marrow space, which must be very much extensive to be
detectable. And so, CT has limited use as an imaging modality
screening for different osseous metastases, in spite of its high
specificity (4). ‘‘Positron emission tomography” (PET) is a
scan technique of molecular imaging basis widely used in
diagnosis of tumoral activity, using ‘‘18F labeled fluoro-
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information in quantitative and qualitative manner about the
tumor cells according to their high rate of metabolism of
glucose (5). PET scanning can identify osseous metastases at
an early stage of growth before host reactions to tumor cells
occur. Early malignant bone marrow infiltration can be
depicted by 18F-FDG PET because of the very early increased
metabolism of glucose in the neoplastic cells (6). The combined
PET/CT is unique as it can scan the whole body in one session,
and it can provide us with the functional and anatomic data in
coregistered images. It combines the value of both CT and
PET in best anatomical localization in the CT and activity of
lesions by the PET scan and so more accuracy in detection
and staging of different malignancies (5). The goal of this study
was to assess the value of combined PET/CT using 18F-FDG
in detection of osseous metastatic lesions compared to isolated
CT in various malignancies.
2. Patients and methods
2.1. Patients
The study is retrospective and population included 53 cancer
patients (38 male patients, 15 female patients; the mean age:
53.5; age range: 33–74). They underwent combined PET/CT
scanning on whole body. Variable indications for PET/CT
examination and they were; 22 patients were referred to the
study for initial staging of the disease and 31 patients at different
disease stages follow up. According to the malignancy type,
the patients were divided into five groups and this was accord-
ing to the primary malignancies type. The primary malignancy
type has been pathologically proven for all patients. Exclusion
criteria were any recent intervention as biopsy or local beam
radiotherapy or therapy by ‘‘granulocyte colony stimulating
factor” within about 1 month from the PET/CT scan.
2.2. PET/CT acquisition and processing
Combined PET/CT scan using a hybrid PET/CT system (Inge-
nuity, TF PET/CT/Philips, the Netherlands) was performed. A
64 multi-slice scanner was the integrated CT system. Both
studies and co-registered CT and PET images were performed
in a single session. The rules of patient preparation were fol-
lowed strictly. Complete fasting except for glucose-free hydra-
tion for about 4–6 h before the injection of 18F-FDG was
instructed to the patients. The scan was performed after IV
injection by about 40–60 min using 3.7 MBq/kg, as a dose
‘‘(maximum dose 370 MBq) equivalent to 0.1 mCi/kg;
(maximum dose = 10 mCi) of 18F-FDG”. The study was
done with patient in supine position. The study was performed
on the whole body from the skull base down to the mid thighs.
A PET scan with different bed positions (5–7) was per-
formed and each with approximately 15 cm axial field of view
for each bed position with 4 mm in-plane spatial resolution
and was covering the same field of view of the CT. The time
of acquisition emission data was about 2 min for each bed
position and in time range between 13 and 17 min.
The parameters of the diagnostic CT scan were as follows:
350 mA, 120 kV, 0.5 s was the tube rotation time, the slice
thickness was 5 mm and 8-mm table feed. incremental recon-
struction about 3 mm. negative oral contrast (e.g. water)for bowel were used and IV contrast administration of
80–120 mL of iodinated contrast agent with low-osmolarity.
A Philips workstation was used to view All CT, PET and
PET/CT images and they were reconstructed in multiplanar
reformation and viewed in different planes for all as well as
‘‘3D maximum intensity projection images (MIP)” PET
images in a video mode. The study protocol was approved
by the local ethics committee.
2.3. Image analysis
A team including a nuclear medicine physician and a radiolo-
gist reviewed and interpreted the PET, CT and the fused PET/
CT images and each was blind to the other’s findings. Both
were aware of the full patient’s history and relevant clinical
data. The bone metastases after that were confirmed by biopsy
or by other imaging modalities as PET, CT, PET/CT and
magnetic resonance imaging (MRI); all were performed during
at least 6 months of follow-up. Reviewing older scans in some
cases was done as well to correlate the recorded lesions.
2.3.1. Lesion based analysis
All focal osseous lesions with abnormally high FDG uptake
were examined, recorded and accurately assessed first quanti-
tatively by the measurement of the ‘‘maximum standardized
uptake value (SUV max)” for every boney lesion. The malig-
nant tumors have high SUV values that are greater than
3.0–3.5. Different pathologies that were detected in the CT por-
tion of study were evaluated and recorded, then each of the
lesions in the fused images of PET/CT was evaluated.
Histopathologic examination, clinical evaluation and imaging
data of follow-up evaluation for at least 6 months were the
standard of reference. A suspected osseous lesion was consid-
ered as a true-positive if the lesions were positive histologically
or if there is remarkable progression at the 6 months of follow-
up. The osseous lesion was considered true-negative when there
is negative histological findings or if the lesion totally disap-
peared or unchanged at the follow-up imaging. Also no clinical
deterioration of the patient for at least 6 months has to be
fulfilled. A false negative osseous lesion was considered when
it was missed by the imaging modality and was positive histo-
logically or progressed on follow-up. On the other hand, a false
positive lesion was detected on the imaging study, yet, proved to
be negative histologically or disappeared or unchanged on
follow-up.
3. Results
53 patients with proven primary malignancy histopathologi-
cally (Table 1), were evaluated for suspected osseous metasta-
sis using combined PET/CT scans. Metastatic osseous deposits
were found in 48 patients, and 5 patients were free from oss-
eous metastases.
There were 386 focal lesions in 48 patients evaluated
(Table 2). Based on CT and PET/CT, 338 lesions were charac-
terized as active metastatic deposits and confirmed histopatho-
logically or on follow-up imaging (Fig. 1). PET/CT enabled
the retrospective detection of 22 lesions missed on CT
(Fig. 2). In 17 focal lesions the CT study was defined as false
positive for malignancy, whereas the PET/CT studies were true
negative (Fig. 3) as these focal lesions were non-viable (healed
Table 1 Total number of cases and their primary malignancy
in 53 patients.
No. of cases Primary malignancy
20 Cancer breast
12 Prostatic carcinoma
7 Bronchogenic carcinoma
9 Lymphoma
5 Colonic carcinoma
Table 2 The results of PET/CT, CT, histopathology and/or
follow-up for assessment of 386 lesions in 48 patients.
No. of focal lesions PET/CT CT Histopathology
and/or follow-up
338 TP TP POSITIVE
22 TP FN POSITIVE
17 TN FP NEGATIVE
4 TN TN NEGATIVE
5 FP TN NEGATIVE
TP: true-positive; TN: true-negative; FP: false-positive; FN: false-
negative.
Added value of combined 18F-FDG PET/CT 455sclerotic deposits). None of these focal lesions changed or
developed activity on 6 months of follow-up. Five lesions are
defined as false positive on PET/CT study as they showed
active tracer uptake; however, their linear distribution along
multiple successive ribs, in a patient with recent history of
trauma to the site of uptake confirmed their benign post
traumatic nature and the lesions disappeared in the follow-
up scan (Fig. 4). The remaining 4 lesions were benign lesions
(hemangiomas and bony islands) being negative on both
PET/CT and CT studies, and interpreted as true negative.
According to the above data we calculated and compared the
performance indices of CT and PET/CT for characterization of
386 lesions in 48 patients (Table 3), as regards sensitivity,
specificity, positive predictive value (PPV), negative predictive
value (NPV) and accuracy (Table 3). PET/CT showed sensitivity
of 100%, specificity of 80.8%, PPV of 98.6%, NPV of 100%Fig. 1 81 years old male with history of lung cancer (squamous
evaluation by PET/CT. (a) CT image shows a large destructive soft ti
deposit. (b) Corresponding PET/CT image shows that the mass is inten
its malignant metastatic nature.and accuracy of 98.7% compared with 93.9%, 34.6%, 95.2%,
29% and 89.9%, respectively, for CT data.
4. Discussion
CT is more sensitive than radiology in detection of osseous
metastases; however, its usefulness is limited in detecting early
bone marrow deposits (7,8). Combined PET/CT images show
accurate localization of the active tracer uptake, identify
healed osseous deposits, that show absent tracer uptake as well
as detect early bone marrow deposits before morphological
changes are evident on CT (9).
In our study a total of 386 lesions were analyzed on both
CT and PET/CT images to evaluate the sensitivity, specificity
and accuracy of each modality and the added value of fused
PET/CT in detection of osseous metastases.
The results showed higher sensitivity of PET/CT study than
CT study alone (100% and 93.9% respectively). This is
explained by the presence of active osseous deposits without
structural abnormalities, that were falsely interpreted as
negative by CT, and integration of PET improved the CT
ability to detect these early marrow based metastases. Also
there are no false negative bony lesions detected on PET/CT
study. These are matched with the results of previous studies
conducted by Nakamato et al. (10), Evangelista et al. (11)
and Schaefer et al. (12).
Regarding the specificity, PET/CT also shows higher
specificity than CT (80.8% and 34.6% respectively). This is
due to presence of false positive lesions on CT study, which
were inactive healed osseous metastases. Again, integration
of PET remarkably improved the CT specificity in diagnosis
of active metastases and identification of those metabolically
inert, malignant looking lesions on CT.
Our study results agree with the results of previously done
studies conducted by Yang et al. (13) and Liu et al. (14),
showing that fused PET/CT improved both CT sensitivity
and specificity.
PET/CT sensitivity is higher than its specificity in our
study. This is attributed to the presence of few lesions falsely
interpreted as positive for metastasis by PET/CT, where there
was no abnormality seen on corresponding CT images, and
proved to be benign post traumatic changes.
The results of both CT and PET/CT were concordant for
most of the lesions (342 lesions out of 386 lesions); however,cell carcinoma), received chemotherapy and referred for status
ssue mass involving the left sacral ala, interpreted as a metastatic
sely avid for 18F-FDG with SUV max reaching 20.46, confirming
Fig. 2 42 years old female with history of bilateral breast cancer (invasive ductal carcinoma grade III) underwent bilateral mastectomy
followed by chemotherapy and radiotherapy. Presented with elevated tumor marker levels and referred for PET/CT assessment. (a) Axial
and sagittal CT image shows no bony abnormalities detected at the scanned bones of axial skeleton, and falsely interpreted as free from
metastases. (b) Corresponding PET/CT images show multiple hypermetabolic marrow based focal osseous lesions at left pubic body and
dorsolumbar vertebrae with SUV max ranging between 7.5 and 9.7, consistent with true active metastatic deposits.
Fig. 3 43 years old female with history of left breast cancer (invasive ductal carcinoma grade II) metastatic to the bones, referred for
assessment by PET/CT study after receiving chemotherapy and radiotherapy. (a) CT image shows a sclerotic lesion at L3 vertebra, falsely
interpreted as a malignant sclerotic bony deposit. (b) PET/CT image shows that the lesion is metabolically inert with no any 18F-FDG
uptake, denoting its non viable nature (healed sclerotic deposit).
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Fig. 4 57 years old female with history of right renal cell carcinoma, underwent right nephrectomy since 3 years and referred for follow-
up PET/CT study; however, she gave history of recent mild trauma to the left side of the back. (a) CT image shows no abnormalities on
the ribs. (b) and (c) PET and PET/CT images show metabolically active lesions at posterolateral aspects of the left 8th, 9th and 10th ribs
arranged in the same linear axis, confirming their benign post traumatic nature.
Table 3 Comparison of performance indices of CT and PET/CT for characterization of 386 lesions in 48 patients (lesion-based
analysis).
No. of lesions TP TN FP FN Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
PET/CT 386 360 21 5 0 100 80.8 98.6 100 98.7
CT 386 338 9 17 22 93.9 34.6 95.2 29 89.9
TP: true-positive; TN: true-negative; FP: false-positive; FN: false-negative; NPV: negative predictive value; PPV: positive predictive value.
Added value of combined 18F-FDG PET/CT 457they were disconcordant for the remaining 44 lesions. When
the results were disconcordant, PET/CT was more accurate
than CT alone in detection and characterization of the bony
lesions and the current study showed that fused PET/CT inter-
pretation accuracy is higher than that of CT alone (98.7% and
89.9% respectively).
5. Conclusion
Combined PET/CT improved the CT ability to detect and
characterize metastatic osseous deposits, which is essential
for proper staging and further management planning.
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